KDR and neoplasm: Among these, anlotinib, as a multi-target anti-angiogenic drug, theoretically inhibits tumor angiogenesis by targeting VEGFR, PDGFR, among others; anti-angiogenic drugs have been proven to improve the tumor immune microenvironment and may synergize with PD-1 inhibitors.